Enhancing cancer immunotherapy using a specific lipid compound
Official title: Tetraacylated lipid A enhancement of checkpoint blocking cancer immunotherapy
Funded at Harvard Medical School · NIH-10994161 · Data updated 2026-11-12
This study is looking at how a natural compound from our gut might help boost the effectiveness of cancer treatments for patients who haven't had success with current therapies, by working alongside a type of treatment that helps the immune system fight cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 4, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $178,294 |
| NIH project number | 5R21CA287104-02 |
| Project ID | NIH-10994161 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients, particularly those with adenocarcinoma, who have not responded to anti-PD-L1 therapy.
✕Less likely to help
Patients who are not diagnosed with cancer or those who have already responded positively to existing immunotherapy treatments may not benefit from this research.
What this research studies
This research investigates how a specific compound derived from the gut microbiome, known as tetra-acylated lipid A, can improve the effectiveness of cancer immunotherapy, particularly for patients who do not respond to existing treatments. The study will explore the interaction between this compound and immune checkpoint inhibitors, which are designed to activate the immune system against cancer. By using animal models, the researchers aim to determine if this compound can enhance the response to anti-PD-L1 therapy, potentially leading to better outcomes for patients with certain types of cancer.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly improves the effectiveness of cancer immunotherapy for patients who currently do not respond to existing therapies.
How similar studies have gone: Previous research has shown promising results in enhancing cancer immunotherapy through microbiome interactions, suggesting that this approach could be a viable and innovative strategy.
Where this research is happening
-
Harvard Medical School
Boston, United States Active
Researchers
- Principal investigator: Kasper, Dennis L. — Harvard Medical School
- Study coordinator: Kasper, Dennis L.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.